Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $137

Cantor Fitzgerald analyst Kristen Kluska has maintained an Overweight rating on PTC Therapeutics (NASDAQ: PTCT) and increased the price target from $130 to $137. This adjustment reflects a positive outlook for the company's performance in the market.